Rhinitis/rhinorrhea (intranasal products):
Indications for: ZETONNA
Treatment of symptoms associated with seasonal and perennial allergic rhinitis.
Adult Dosage:
One actuation in each nostril once daily (37mcg/actuation); max 74mcg/day.
Children Dosage:
<12yrs: not established.
ZETONNA Warnings/Precautions:
Conduct nasal examination before starting treatment. Discontinue if nasal erosion, ulceration, perforation, or Candida infection occurs. Avoid use in patients with recent nasal ulcers/surgery/trauma until healed. Active or quiescent respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, parasitic, or ocular herpes simplex). If exposed to measles or chickenpox, consider immunoglobulin prophylactic therapy. Monitor for acute adrenal insufficiency if prolonged systemic corticosteroid therapy is replaced with topical steroids. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually) and other nasal cavity changes. Monitor for vision changes or in those with a history of increased intraocular pressure, glaucoma or cataracts. Monitor for growth suppression in children. Avoid spraying in eyes or directly onto the nasal septum. Pregnancy. Nursing mothers.
ZETONNA Classification:
Glucocorticoid.
ZETONNA Interactions:
May be potentiated by ketoconazole.
Adverse Reactions:
Nasal discomfort, headache, epistaxis; hypersensitivity reactions, nasal ulceration, nasal septal perforation, Candida infection, impaired wound healing.
Drug Elimination:
Fecal (66%), renal (≤20%).
How Supplied:
Nasal aerosol—6.1g (60 actuations)
